Core Viewpoint - The article discusses the innovative drug technology "molecular glue degraders" that can target and eliminate "undruggable" disease-causing proteins, offering new hope for treating complex diseases like cancer and Alzheimer's [4][11]. Group 1: Technology and Innovation - The "molecular glue degraders" can induce cells to mark specific disease-causing proteins for destruction, addressing the limitations of traditional drug development [4]. - A new method developed by Dr. Jiang Hai allows for low-cost and efficient identification of hit compounds for molecular glue degraders, significantly speeding up the drug discovery process [5][12]. - The DEFUSE platform can screen up to 30,000 compounds in a week, providing a high-throughput solution for identifying potential drug candidates [5][15]. Group 2: Company Overview - Dito Bio was founded by Dr. Jiang Hai in 2023, focusing on the development of molecular glue degraders and utilizing the DEFUSE platform for compound screening [5][12]. - The company has adopted a dual-track strategy, collaborating with pharmaceutical companies to develop drugs while also independently researching and developing its own drug candidates [18][21]. - Dito Bio completed a Pre-A round of financing in July 2023, with investments from Junlian Capital and Jiuhe Venture Capital [5]. Group 3: Market and Industry Context - Major pharmaceutical companies like Novartis and BMS are also investing in molecular glue degraders, indicating a growing interest in this area of drug development [5]. - The article highlights the challenges faced in the industry, particularly the difficulty in discovering hit compounds due to the lack of systematic methods [5][11]. - The potential for molecular glue degraders is significant, as they offer a new pathway for treating diseases that have been historically difficult to target with traditional drugs [4][11]. Group 4: Future Plans - Dito Bio aims to produce a wider variety of hit compounds over the next 10 to 15 years, leveraging the DEFUSE platform to accelerate drug development for important disease targets [23]. - The company plans to focus on the oncology field for its drug pipeline, believing that having proprietary drug products will provide a long-term valuation anchor [22].